ASH 2017: Rivaroxaban Reduces Recurrence of Venous Thromboembolism Significantly More Than Dalteparin
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Only registered members have full access to PracticeUpdate content.